Shares of CVS Caremark
How it got here
The demise of the health-care business has been greatly exaggerated, and CVS is capitalizing on continued growth in the pharmaceutical industry. Strong financial performance has helped drive the stock to a new high, and right now it appears that the company can continue to improve performance.
In the first quarter of 2012 the company reported a 19.9% increase in revenue to $30.8 billion and a 14.7% increase in adjusted earnings per share to $0.65. Management also raised full-year guidance to earnings of $3.23 to $3.33 per share on stronger confidence that growth will continue.
The pharmacy services segment has driven growth over the past year, growing 32.3% to $18.3 billion in the first quarter. The company's acquisition of the Medicare prescription drug plan from Universal American Corp. helped drive that growth.
The success CVS has had over the past year on the market hasn't been an industrywide trend, as you can see below. Walgreen
From a valuation perspective, CVS still has some upside potential if growth can increase return on assets.
|Price/Book||Profit Margin||Return on Assets||Forward P/E|
Source: Yahoo! Finance.
Right now, Walgreens may look like a better buy based on forward P/E, return on assets, and profit margin, but the company isn't growing nearly as quickly as CVS right now, making the comparison a bit more even.
CVS has performed well on the market over the past year and I don't think the outperformance will stop. CVS offers a convenient retail product, and pharmacy sales don't show any signs of slowing. The company's recent earnings release and increased guidance makes me confident that there is more upside to come, especially if the economy continues its slow recovery.
How high can the stock go? I think a price-to-earnings ratio of 15 times 2013 earnings is reasonable, especially if estimates keep going up, indicating another 20% of upside.
The CAPS community seems to agree, giving the stock a four-star rating from 1,649 out of 1,717 players who have rated the stock. I'm also making a CAPScall, adding an outperform call on My CAPS page, which can be found here.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Is CVS Health Corporation a Buy in 2018?
There are good reasons to buy the pharmacy giant -- but good reasons to stay away, too.
These 3 Healthcare Stock Dividends Could Soar If Trump Signs a Tax Reform Bill
A corporate tax rate reduction will raise some boats a lot higher than others.
5 Top Stocks for December
Rebalancing your portfolio for the new year? These stocks should be at the top of your buy list.